{"id":"NCT00743652","sponsor":"Pfizer","briefTitle":"Study Evaluating the Impact of the 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Alaskan Native Children.","officialTitle":"A Phase 3, Open Label Trial Evaluating the Safety, Immunogenicity and Impact of 13-valent Pneumococcal Conjugate Vaccine in Alaskan Native Children.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-01","primaryCompletion":"2010-09","completion":"2010-09","firstPosted":"2008-08-29","resultsPosted":"2012-02-10","lastUpdate":"2012-03-15"},"enrollment":373,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Pneumococcal Disease","13-valent Pneumococcal Vaccine"],"interventions":[{"type":"BIOLOGICAL","name":"13-valent Pneumococcal Conjugate Vaccine","otherNames":[]},{"type":"BIOLOGICAL","name":"13-valent Pneumococcal Conjugate Vaccine","otherNames":[]},{"type":"BIOLOGICAL","name":"13-valent Pneumococcal Conjugate Vaccine","otherNames":[]},{"type":"BIOLOGICAL","name":"13-valent Pneumococcal Conjugate Vaccine","otherNames":[]},{"type":"BIOLOGICAL","name":"13-valent Pneumococcal Conjugate Vaccine","otherNames":[]}],"arms":[{"label":"Group1","type":"EXPERIMENTAL"},{"label":"Group 2","type":"EXPERIMENTAL"},{"label":"Group 3","type":"EXPERIMENTAL"},{"label":"Group 4","type":"EXPERIMENTAL"},{"label":"Group 5","type":"EXPERIMENTAL"}],"summary":"This study is to evaluate the safety, immunogenicity and impact of 13-valent Pneumococcal conjugate vaccine in Alaskan Native Children.","primaryOutcome":{"measure":"Percentage of Participants Achieving Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody Level â‰¥0.35 Micrograms Per Milliliter (Mcg/mL) 1 Month After the Infant Series","timeFrame":"28 to 56 days after vaccination 3 for Group 1, after vaccination 2 for Group 2, and after vaccination 1 for Group 3.","effectByArm":[{"arm":"13vPnC Group 1 (3 Doses Infant Series and 1 Toddler Dose)","deltaMin":100,"sd":null},{"arm":"13vPnC Group 2 (2 Doses Infant Series and 1 Toddler Dose)","deltaMin":100,"sd":null},{"arm":"13vPnC Group 3 (1 Dose Infant Series and 1 Toddler Dose)","deltaMin":100,"sd":null}],"pValues":[]},"eligibility":{"minAge":"42 Days","sex":"ALL","healthyVolunteers":true,"inclusionCount":3,"exclusionCount":1},"locations":{"siteCount":21,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=6096A1-3010&StudyName=Study%20Evaluating%20the%20Impact%20of%20the%2013-valent%20Pneumococcal%20Conjugate%20Vaccine%20%2813vPnC%29%20in%20Alaskan%20Native%20Children."]},"adverseEventsSummary":{"seriousAny":{"events":21,"n":151},"commonTop":["Pyrexia","Injection site erythema","Injection site swelling","Convulsion","Crying"]}}